Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 1
2012 3
2013 3
2014 1
2015 1
2016 10
2017 14
2018 16
2019 14
2020 15
2021 17
2022 17
2023 16
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Lifitegrast.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999933 Free Books & Documents. Review.
Breastmilk levels of lifitegrast have not been measured in humans. Because absorption from the eye is limited, ophthalmic lifitegrast would not be expected to cause any adverse effects in breastfed infants. ...
Breastmilk levels of lifitegrast have not been measured in humans. Because absorption from the eye is limited, ophthalmic lifitegr …
Lifitegrast for the treatment of dry eye disease in adults.
Donnenfeld ED, Perry HD, Nattis AS, Rosenberg ED. Donnenfeld ED, et al. Expert Opin Pharmacother. 2017 Oct;18(14):1517-1524. doi: 10.1080/14656566.2017.1372748. Epub 2017 Sep 4. Expert Opin Pharmacother. 2017. PMID: 28841079 Review.
The aim of this article is to summarize the preclinical and clinical data on lifitegrast and discuss how lifitegrast may fit into the current treatment landscape for DED. ...Future research should include evaluation of whether lifitegrast can be used in combi …
The aim of this article is to summarize the preclinical and clinical data on lifitegrast and discuss how lifitegrast may fit i …
Lifitegrast: a novel drug for patients with dry eye disease.
Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Haber SL, et al. Ther Adv Ophthalmol. 2019 Aug 22;11:2515841419870366. doi: 10.1177/2515841419870366. eCollection 2019 Jan-Dec. Ther Adv Ophthalmol. 2019. PMID: 31489402 Free PMC article. Review.
A PubMed search (1946 to December 2018) using the terms lifitegrast and SAR 1118 was conducted to identify relevant articles. In vitro or in vivo evaluations of lifitegrast published in the English language were eligible for inclusion. ...
A PubMed search (1946 to December 2018) using the terms lifitegrast and SAR 1118 was conducted to identify relevant articles. In vitr …
Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
Keating GM. Keating GM. Drugs. 2017 Feb;77(2):201-208. doi: 10.1007/s40265-016-0681-1. Drugs. 2017. PMID: 28058622 Review.
Lifitegrast ophthalmic solution 5% (Xiidra) was recently approved in the USA for the treatment of dry eye disease. ...Lifitegrast ophthalmic solution 5% was generally well tolerated. In conclusion, lifitegrast ophthalmic solution 5% provides a new option for …
Lifitegrast ophthalmic solution 5% (Xiidra) was recently approved in the USA for the treatment of dry eye disease. ...Lifitegrast …
Lifitegrast, Bezlotoxumab, and Sugammadex sodium.
Hussar DA, Cheeseman RS 2nd. Hussar DA, et al. J Am Pharm Assoc (2003). 2017 Mar-Apr;57(2):284-287. doi: 10.1016/j.japh.2017.02.004. J Am Pharm Assoc (2003). 2017. PMID: 28285777 Review. No abstract available.
Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
Li JX, Tsai YY, Lai CT, Li YL, Wu YH, Chiang CC. Li JX, et al. J Clin Med. 2022 Aug 26;11(17):5014. doi: 10.3390/jcm11175014. J Clin Med. 2022. PMID: 36078948 Free PMC article. Review.
However, lifitegrast showed higher risks for ocular and non-ocular treatment-emergent adverse events (TEAEs) overall or at a mild or moderate level. ...Overall, most of the adverse events are tolerable. Lifitegrast can alleviate refractory DED and improves patients' …
However, lifitegrast showed higher risks for ocular and non-ocular treatment-emergent adverse events (TEAEs) overall or at a mild or …
Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program.
Chan CC, Prokopich CL. Chan CC, et al. J Pharm Pharm Sci. 2019;22(1):49-56. doi: 10.18433/jpps29895. J Pharm Pharm Sci. 2019. PMID: 30636670 Free article. Review.
Four clinical trials have shown that lifitegrast is well tolerated and effective in improving symptoms and signs of DED over 12 weeks. ...In this review, we discuss lifitegrast's novel mechanism of action and provide an overview of its clinical trial program....
Four clinical trials have shown that lifitegrast is well tolerated and effective in improving symptoms and signs of DED over 12 weeks …
Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.
Godin MR, Gupta PK. Godin MR, et al. Clin Ophthalmol. 2017 May 22;11:951-957. doi: 10.2147/OPTH.S117188. eCollection 2017. Clin Ophthalmol. 2017. PMID: 28579745 Free PMC article. Review.
Lifitegrast is an integrin antagonist that decreases inflammation on the ocular surface, thereby improving dry eye disease (DED). ...Lifitegrast is now available for use in clinical practice....
Lifitegrast is an integrin antagonist that decreases inflammation on the ocular surface, thereby improving dry eye disease (DED). ... …
Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease.
Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M. Chhabra S, et al. Leuk Lymphoma. 2020 Apr;61(4):869-874. doi: 10.1080/10428194.2019.1695049. Epub 2019 Nov 25. Leuk Lymphoma. 2020. PMID: 31762357
We evaluated the efficacy and safety of lifitegrast (5% ophthalmic solution) in patients with ocular GVHD in a single-institution retrospective cohort study of eighteen allogeneic transplant recipients who received topical lifitegrast for oGVHD treatment. ...Lifi …
We evaluated the efficacy and safety of lifitegrast (5% ophthalmic solution) in patients with ocular GVHD in a single-institution ret …
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.
Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Perez VL, et al. Ocul Surf. 2016 Apr;14(2):207-15. doi: 10.1016/j.jtos.2016.01.001. Epub 2016 Jan 22. Ocul Surf. 2016. PMID: 26807723 Free article. Review.
The latest advances in the understanding of the pathophysiology of DED have directed the focus of recent drug development to target the inflammatory pathways involved in the disease. Lifitegrast is a novel small molecule integrin antagonist that inhibits T cell-mediated in …
The latest advances in the understanding of the pathophysiology of DED have directed the focus of recent drug development to target the infl …
118 results